Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes

Name: Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes
Creator: Vivli
Published: 2025-12-08 23:14:34
License: 暂无描述

DataCite Commons2025-12-08 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/00002478/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to compare the efficacy of Alogliptin, once daily (QD), taken by itself and with pioglitazone on postprandial lipid measures in type 2 diabetes.

提供机构：

Vivli

创建时间：

2018-10-27